Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-031266
Filing Date
2022-06-06
Accepted
2022-06-06 08:02:09
Documents
3
Period of Report
2022-06-06

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea161163-6k_nlspharma.htm 6-K 15499
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS APPOINTS CHAD C. HELLMANN AS CHIEF FINA ea161163ex99-1_nlspharma.htm EX-99.1 13862
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11018
  Complete submission text file 0001213900-22-031266.txt   45673
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 22996741
SIC: 2834 Pharmaceutical Preparations